

Reference

- Abaza H (2000):** Hepatitis C virus (HCV) - related hepato-cellular carcinoma. Arab J.G., Vol. 1(2): 137-141.
- Abd El-Baset MZ, Lashin AH, Abo-Senna AA and Biomy HA (2006):** Evaluation of liver fibrosis markers in chronic liver diseases". MD thesis in Banha Faculty of Medicine Results. Page 172-188.
- Abdel-Wahab MF, Zakaria S, kamel M and et al., (1994):** High seroprevalence of hepatitis C virus infection among risk groups in Egypt. Am. J. Trop. Med. Hyg.; 51(5):563-547.
- Abdel-Wahab MF, Zakeria S, Kamel M and et al.,(1994):** High seroprevalence of hepatitis C virus infection among risk groups in Egypt. Am. J.Trop. Med. Hyg.; 51 (5):563-547.
- Abdi W, Milla JC and Mezey E (1979):** Sampling variability on percutaneous liver biopsy. Arch. Intern. Med.; 139:667-669.
- Abo Al-Azm A and El-Sheikh M (1996):** prevalence of hepatitis C and B viruses in Gharbia Governorate rural area in comparison with a group of blood donors. JHGID; 4(4): 31-39.
- Adel-Wahab MF, Zakaria S, Kamel M and et al., (1994):** High seroprevalence of hepatitis C virus infection among risk groups in Egypt. Am. J. Trop. Med. Hyg.; 51(5): 563-547.
- Adler M, Frotscher B, Thiry P and Gustot T (2004):** Non invasive markers of liver fibrosis in hepatitis C. Aeta Gastroenterol Belg. 67(3): 278-81.
- Afdhal NH and Nunes D (2004):** Evaluation of liver fibrosis: A concise review. Am J. Gastroenteral. 127: 1704-1713.

- Afdhal NH and Nunes D (2004):** Evaluation of liver fibrosis: a concise review. *Am J Gastroenterol*, 99 (6): 1160-74.
- Alberti A, Vanio A, Boccato S and et al., (2005):** Pathogenesis and incidence of hepatic steatosis in hepatitis C. *Aliment phanmacol. Thre*; 22 (2) 74-8.
- Alexandrakis MG, Moschan J, Kyriako DS and et al., (2001):** Biochemical markers differenctiating cirrhotic from malignant ascites. *Intel. J. Biol.*; 16(1): 45-49.
- Alpini G, McGill JM and Larusso NF (2002):** The pathobiology of biliary epithelia. *Hepatology*; 35:1256-1268.
- Alter HJ and Seeffle B (2000):** Recovery, perisistence and sequalae in hepatitis C virus infection: a persepective on long term outcome. *Semin liver Dis.* 20(1) 17-35.
- Alter HJ, Cantilena CC, Melpolder J and et al., (1997):** Hepatitis C in asymptomatic blood donors. *Hepatology*, 26(Suppl.1): 29S-33S.
- American Society For Biochemistry and Molecular biology (2000):** Reprinted with permission from fridman 72 "phenotypic changes of HSC, upon activation during liver injury".
- Aparicio T and Lehy T (1999):** Metalloprotéinases matricielles en pathologie digestive. *Gastroentérol Clin Biol*; 23: 330-341.
- Arthur MJ (2004):** Degradation of matrix proteins in liver fibrosis. *Path. Res. Praact.*; 190:825-832.
- Arthur MJP (1998):** Fibrosis and matrix degradation. *Digestion*; 59: 376-380.
- Attallah AM, Zahran F, Ismail H and et al., (2007):** Immuno-chemical identification and detection of serum fibronectin in liver fibrosis

patients with chronic hepatitis C. J Immunoassay Immunochem. 28(4): 331-42.

Aubec, Oberti F, Korali N and et al., (1999): Ultrasonnugraphic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol. 30:472-478.

Bach N, Thung SN and Schaffner F (1992): The histological changes in chronic hepatitis C and autoimmune hepatitis: A comparative analysis. Hepatology, 15 (4): 572-577.

Bacq Y, Schilio Y, Brechot JF and et al., (1993): Decrease of haptoglobin serum level in patients with chronic viral hepatitis C. Gastroenterol. Clin. Biol.; 17(5): 364-369.

Bataller R, Brenner DA (2005): Liver fibrosis. J Clin Invest; 115: 209-18.

Bedossa P and Poynard T (1994): The METAVIR Cooperative Group Inter-and intra-observer variation in the assessment of liver biopsy of chronic hepatitis C. Hepatology; 20(1):15-20.

Bedossa P and Poynard T (1996): For the METAVIR Cooperative Group: An algorithm for the grading of activity in chronic hepatitis C. Hepatology, 24:289-293.

Bedossa P and Poynard T (1996): An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology, 24: 289-293.

Bendinelli M, Vatteroni ML, Maggi F and Pistello M (1999): Hepatitis C virus: Biology, pathogenesis, Epidemiology, Clinical description and diagnosis. J Viral Methods, 77(2): 207-15.

- Benhamou Y, Bochet M, Di Martino V and et al., (1999):** Liver fibrosis progression in HIV and HCV coinfecting patients. The multivire Group. *Hepatology*; 30: 1054-58.
- Berdichevski F (2001):** Complexes of tetraspanins with integrins: more than meets the eye. *J. Cell. Sci*; 114: 4143-4151.
- Bianchi L, DeGroote J, Desmet VJ and et al., (1997):** Acute and chronic hepatitis revisited. *Lancet*; 2:914-919.
- Blubak ME, Porayko MK, Krom RAF and et al., (1991):** Complications of liver biopsy in liver transplant patients: increased sepsis associated with choledochojejunostomy. *Hepatology*; 14: 1603-1605.
- Boeker RH, Haberkorn CI, Michels D and et al.,(2002):** Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. *Clin Chim Acta*; 316: 71-81.
- Bonacini M, Hadi G, Govindarajan S and Lindsay KL (1997):** Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. *Am J. Gastroenterol*; 92(8):1302-4.
- Bonkovsky HI and Woolley JM (1999):** Reduction of health-related quality of life in chronic hepatitis C *Hepatology*, 29: 264-70.
- Boyer JL and Klatskin G (1970):** Pattern of necrosis in acute viral hepatitis: Prognostic value of bridging (subacute hepatic necrosis). *N. Engl. J. Med.*; 283: 1063-1071.
- Breet F, DeZanger R, Baekeland M and et al., A (1995):** Structure and dynamics of the fenestrae-associated cytoskeleton of rat liver sinusoidal endothelial cells. *Hepatology*; 21: 180.

Breitkopf K, Lahme B, Tag CG and Gressner AM (2001): Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. *Hepatology*; 33: 387-396.

Buscarini L, Fornari F, Bolondi L and et al., (1990): Ultrasound – guided fine- needle biopsy of focal liver lesions: techniques, diagnostic accuracy and complications. *J. Hepatol.*; 11:344.

Cadranel JF and Philippe M (2002): Prothrombin index decrease: a useful and reliable marker of extensive fibrosis. *Eur. J. Gastroenterol. Hepatol.*; 14(10): 1057-1059.

Campbell MJ and Machin (1993): Medical Statistics. A common sense approach. 2nd ed. John Wiley and Sons. New York, Chichester, Brishbance, Toronto and Signapore.

Carlioni V, DeFranco RMS, Caligiuri A and et al., (2002): Cell adhesion differentially regulates platelet-derived growth factor-induced ERK/MAP- Kinase and PI3- Kinase activation in human hepatic stellate cells. *Hepatolaogy*; 36:582-591.

Carlioni V, Romanelli RG, Pinzan M and et al., (1997): Focal adhesion Kinase and phospholipase-C involvement in cell adhesion and migration of human hepatic stellate cells. *Gastroenterol.*; 112: 522-531.

Carreno V (2006): Occult hepatitis C virus infection A new form of hepatitis C. *World J Gastroenterol.* 12(49): 6922-6925.

Cassiman D and Roskams T (2002): Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. *J. Hepatol.*; 37:527-535.

Castera L, Denis J, Babany G and Roudot Thoraval F (2007):

"Evolving practices of non-invasive markers of liver fibrosis in patients with chronic hepatitis C in France: Time for new guidelines?". J. Hepatol. 46(3): 528-29.

Castera L, Hartmann DJ, Chapel F and et al., (2000):

Serum laminin and type IV collagen are accurate markers of histologically severe alcoholic hepatitis in patients with cirrhosis. J. Hepatol.; 32:412.

Castera L, Vergniol J, Foucher J and et al., (2005):

Prospective comparison of transient elastography, Fibrotest, APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology , 128: 343-50.

Castillo I, Pardo M, Bartolome J and et al.,(2004):

Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis ; 189: 7-14

Catarino RM, Lopez JD, Forones NM and Parise ER (2005):

Laminin concentration in as cites of patients with hepatic cirrhosis and peritonol concinomatuisis. Braz. J Med Biol Res.; 38(2): 271-6.

Caturelli E, Giacobbe A, Facciorusio D and et al., (1996):

Percutaneous biopsy in diffuse liver disease: increasing diagnostic yield and decreasing complication rate by routine ultrasound assessment of puncture site. Am J Gastroenterol; 91: 1318-1321.

Celle G, Savarino V, Picciotto A, and et al., (1988):

Is hepatic ultrasonography a valid alternative tool to liver biopsy? Report on 507 cases studied with both techniques. Dig Dis Sci; 33:467–71

- Charlton M (2003):** Normal history of hepatitis C and outcomes following liver transplantation. Clin Liver Dis., 2003 Aug; 7(3); 585-602.
- Chen SL and Morgan TR (2006):** The natural history of hepatitis C virus (HCV) infection. Int J Med Sci.;3(2):47-52.
- Chevalicz C and Pawlotsky JM (2006):** Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV-related liver disease. International Journal of Med. Sciences. 3(2): 35-44.
- Chevaliez S and Pawlotosky JM (2006):** Hepatitis C virus serologic and virologic tests and clinical diagnosis of HCV related liver diseases. International Journal of Medical Science (Int. J. Med. Sci) 2006; 3(2):35-40.
- Choo QL, Kuo G, Weiner AJ and et al.,(1989)** Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science ;244(4902):359-62.
- Christoffersen P, Poulsen H and Skeie E (1970):** Focal liver necrosis accompanied by infiltration of granulocytes arising during operations. Acta Hepato- Splenologica; 17:240-245.
- Christoffersen P, Poulsen H and Skeie E (1970):** Focal liver necrosis accompanied by infiltration of granulocytes arising during operations. Act Hepato-Splenologica; 17: 240-245.
- Chung RT, Andersen J, Volberding P and et al., (2004)** Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV co-infected persons. N Engl J Med, 351: 451-9.
- Chung YH, Kim JA, Song BC and et al., (2000):** Expression of transforming growth factor-Alpha-mRNA in livers of patients with

chronic viral hepatitis and hepato-cellular carcinoma. Cancer; 89: 977.

Clark JM and Diehl AM (2003): Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA; 289: 3000-3004.

Colin C, Lanoir D, Tovzet S and et al., (2001): Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of literatures. J virol Hepat. 8:87-95.

Conte D, Fraquelli M, Prati D and et al., (2000): Prevalence and clinical comes of chronic HCV infection and rate of HCV vertical transmission in a cohort of 15, 250 pregnant women. Hepatology. 2000 May; 31(3):751-5.

Coverdale SA, Samarasinghe DA, Lin R and et al., (2003): Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. Am. J. Gastroenterol.; 98(6): 1384-1390.

Croquet V, Vuillemin E, Ternisien C and et al., (2002): Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol ; 14: 1133-1141.

Dalgard O, Bjørø K, Hellum KB and et al (2004): Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology, 40: 1260-5.

Daniel WW (1987): Biostatistics, a formulation for analysis in the health science. 4th ed., John Wiley and Sons. New York, Chichester, Brishbance, Toronto and Signapore.

- Darwish M, Faris R, Clemens J and et al., (1996):** High seroprvalence of hepatitis A, B, C and D viruses in residents in an Egyptian village in the Nile Delta. A pilot study. *Am. J. Trop. Med. Hyg.*; 54(6): 554-558.
- Davis GL, Wong JB, McHutchison JG and et al.(2003)** Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. *Hepatology* , 38: 645-52.
- De Groote J, Desmet VJ, Gedik P and et al., (1968):** A classification of chronic hepatitis. *Lancet*; 2: 626-628.
- Desmet V, Roskams T and VanEyken P, (1995):** Ductular reaction in the liver. *Pathol. Res. Pract.*; 191:513-524.
- Desmet VJ, Gerber M, Hoofnagle JH and et al., (1994):** Classification of chronic hepatitis: diagnosis, grading and staging. *Hepatology*; 19:1513-1520.
- Deuffic S, Buffat L, Poynard T and Valleron AJ (1999):** Modelling the hepatitis C virus epidemic in France. *Hepatology*; 29: 1596-601.
- Dienstag JL (2002):** The role of liver biopsy chronic hepatitis C. *Hepatology*; 36(1):S152-S160.
- Dixon AK, Nunez DJ, Bradley JR and et al., (1987):** Fail me of percutaneous liver biopsy: anatomical variation. *Lancet*; 2:437-439.
- Dobryszcha S, Wanda A, Zolzislaw R and et al., (1987):** Haptoglobin: An acte phase reactant. *Arck.Immunol.Ther.Exp.*; 33(5): 617-622.
- Dotter CT (2004):** Catheter biopsy. Experimental technique for transvenous liver biopsy. *Radiology*; 82: 312-314.

- Dufour JF, DeLellis R and Kaplan MM (1997):** Reversibility of hepatic fibrosis in autoimmune hepatitis. *Ann Intern Med.* 1; 127(11): 981-5.
- Duseiko GM (1997):** Hepatitis C infection: from virology to management, In *Hepatitis C (1997): Essay and Expert opinions on its Natural History, Epidemiology, Diagnosis and Therapy.* Abbott Diagnostics Division, pp 5-25.
- Dziegielewska KM (1986):** Synthesis of plasma proteins in fetal, adult and neoplastic brain tissue. *Dev. Biol.*; 115:93.
- El-Gindy I, El-Rahman AT, El-Alim MA and et al., (2003):** Diagnostic potential of serum matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 as non-invasive markers of liver fibrosis in patients with HCV- related chronic liver disease. *Egypt. J. Immunol.*; 10(1):27-35.
- Ellis G, Goldberg DM, Spooner RJ and et al., (1987):** Serum enzyme tests in diseases of the liver and biliary tree. *Am. J. Clin. Pathol.*; 70: 248-258.
- El-Sayed MN, Gomatos PJ, Rodier GR and et al., (1996):** Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, HCV, HIV, Treponema pallidum infection: association of HCV infection with specific regions of Egypt. *Am J Trop med Hyg*; 55(2): 179-84.
- El-Sayed NM, Gomatos PJ, Rodier GR and et al., (1996):** Seroprevalence survey of Egyptian tourism workers for hepatitis B virus, hepatitis C virus, human immunodeficiency virus and treponema pallidum infections: association of hepatitis C virus

infection with specific regions of Egypt. Am. J. Trop. Med. Hyg. ; 55(2): 179-184.

ElSerag HB, Hampel H, Yeh C and Rabeneck L (2002): Extrahepatic manifestations of hepatitis C virus infection among united states male veterans. Hepatology; 36(6): 1439-45.

El-Zayadi A, Abaza H, Shawky S and et al., (2001): Prevalence and epidemiological features of hepatocellular carcinoma in Egypt-a single center experience. Hepatology Research ; 19: 170-179.

Engström – Laurent A, Löf L, Nyberg A and Schröder T.(1985): Increased serum levels of hyaluronan in liver disease. Hepatology ; 5: 638-642.

Eriksson S, Fraser JRE, Laurent TC and et al.,(1983): Endothelial cells are a site of uptake and degradation of hyaluronic acid in the liver. Exp Cell Res ; 144: 223-228.

Esmat G, Metwally M, Zalata KR and et al., (2007): Evaluation of serum biomarkers of fibrosis and ingmy in Egyptian patients with chronic hepatitis C. J. Hepatol; 46(4): 620-7.

Fabris P, Marranconi F, Bozzola L and et al., (1999): Fibrogenesis-serum markers in patients with chronic hepatitis C treated with alpha-IFN. J. Gastroenterol.; 34: 345.

Fattovich G, Pantalena M, Zagni I and et al., (2002): European Concerted Action of HCV-related cirrhosis Am J Gastroenterol. 2002 Nov; 97*(11): 2886-95.

Ferni MA, Artuso D, Gerken G and et al., (1995): Focal lymphocytic aggregates in chronic hepatitis C: occurrence, immuno-histochemical characterization and relation to markers of autoimmunity. Hepatology; 22:389.

- Fisher L, Gill G, Farrester M and et al., (1976):** Quantitation of acute phase proteins post operatively. Detection and monitoring of complications. Am. J. Clin. Pathol.; 66:840.
- Fontana RJ and Lok ASF (2002):** Noninvasive monitoring of patients with chronic hepatitis C. Hepatology; 36:S57–S64
- Forbes SJ, Russo F, Burra P and et al., (2003):** A significant proportion of myofibroblasts in human liver cirrhosis are of bone marrow origin. Hepatology; 38, Suppl. 1:341 A.
- Forns X, Ampurdanés S, Llovet JM and et al., (2002):** Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 36(4pt 1): 986-92.
- Frank C, Mohamed MK, Strickland GT and et al., (2000):** The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet, 355(9207): 887-91.
- Friedman LS (2004):** Controversies in liver biopsy: who, where, when, how, why?. Curr Gastroenterol Rep; 6(1): 30-36.
- Friedman LS, Mantin P and Munoz SJ (2002):** Laboratory methods for evaluation of the patients with liver disease. In Zakim D, Boyer TD eds. Hepatology: A textbook of liver disease, 8th edn. Philadelphia: Saunders 661-708.
- Friedman SL (2003):** Liver fibrosis- from bench to bedside. J. Hepatol.; 38: S38-S53.
- Friedman SL (1999):** Cytokines and fibrogenesis. Sem Liver Dis , 19: 129-140.

- Gebo KA, Herlong HF, Torbenson MS and et al., (2002):** Role of liver biopsy in management of chronic hepatitis C: A systematic review. *Hepatology*; 36: S161- S172.
- George DK, Ramm GA, Walker NI and et al., (1999):** Elevated level of serum type IV collagen: a sensitive indicator of the presence of cirrhosis I haemochromatosis. *J. Hepatol.*; 31: 47.
- George J, Roulot D, Koteliansky VE and et al., (1999):** In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis. *Proc. Natl. Acad. Sci. USA*; 69: 12719-12724.
- Gerlach JT, Diepolder HM, Zachoval R and et al., (2003):** Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. *Gastroenterology*; 125: 80–88.
- Ghaffar YA, Fattah SA, Kamel M and et al., (1991):** The impact of endemic schistosomiasis on acute viral hepatitis. *Am. J. Trop. Med. Hyg.*; 45:743-750.
- Ghosn J, Leruez-Ville M and Chaix ML (2005):** Sexually transmission of HCV. *Presse Med*, 2005 Aug. 27; 34(14):1034-8.
- Giannini E, Risso D, Botta F and et al.(2003)** Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. *Arch Intern Med* ; 163: 218-224.
- Goldberg DM (1980):** Structural, Functional and clinical aspects of gamma glutamyl transferase. *CRC Crit. Rev., Clin. Lab. Sci.*; 12: 1-58.

- Gordon SC, Fang J W, Silverman AL and et al., (2000):** The significance of baseline serum alanine aminotransferase on pretreatment disease characteristics and response to therapy in chronic hepatitis C. *Hepatology*; 32: 400-404.
- Gressner AM, Weiskirchen R, Breitkopf K and Dooley S (2002):** Roles of TGF-beta in hepatic fibrosis. *Front Biosci*, 7:2247-50.
- Gressner AM (1998):** The cell biology of liver fibrogenesis-an imbalance of proliferation, growth arrest and apoptosis of myofibroblast. *Cell Tissue Res*; 292: 447-452.
- Gretch DR, Dela Rosa C, Carithers RL and et al., (1995):** Assessment of hepatitis C viremia using molecular amplification technologies; correlations and clinical implications. *Ann Intern Med*. 123(5): 321-9.
- Grigorescu M (2006):** Non-invasive biochemical markers of liver fibrosis. *J Gastrointest. Liver Dis.*; 15(2): 149-59.
- Guéchet J, Laudat A, Loria A and et al., (1996):** Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. *Clin Chem*; 42: 558- 563.
- Guechet J, Loria A, Sefaty L and et al., (1995):** Serum hyaluronan as a marker of liver fibrosis in chronic hepatitis C: effect of alpha-interferon therapy. *J Hepatol*, 22:22-26.
- Guéchet J, Poupon RE and Poupon R (1995):** Serum hyaluronan as a marker of liver fibrosis. *J Hepatol*; 22 (suppl 2): 103-106.
- Guechet J, Serfaty L, Bonnard A and et al., (2000):** Prognostic value of serum hyaluronan in patients with compensated HCV cirrhosis. *J. Hepatol.*; 32: 447.

- Guha N and Iredale JP (2007):** Clinical and diagnostic as peer, of Cirrhosis. Page 619-634. Textbook of hepatology "from basic science to clinical practice". 3rd Edition.
- Hadziyannis SJ and et al., (2004)** Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med, 140: 346-55.
- Halfon P, Bourliere M, Pénaranda G. and et al., (2005):** Accuracy of hyalurolnic acid level for predicting liver fibrosis stager in patients with chronic hepatitis C. Comp. Hepatol. 4: 6.
- Hamasaki M (1996):** Clinical investigation of haemolytic anemia Nippon Rinsho; 54(9): 2407-2410.
- Hashimoto E, Ludwig J, MacCarty RL and et al., (1989):** Hepatoportal arteriovenous fistula: morphologic features studied after orthotopic liver transplantation. Hum. Pathol.; 20:707.
- Hassoba HM, Bzowej N, Berenguer M and et al. (1999):** Evolution of viral quasi-species in interferon-treated patients with chronic C virus infection. J. Hepatol. 31:618.
- Heathcote J. and Main J. (2005).** Treatment of hepatitis C Journal of Viral Hepatitis, 2005, 12, 223–235
- Heller T, Sobao Y, Mizukoshi E and et al. (2003)** HCV exposure in humans: stimulation of cellular, but not humoral immune responses in the absence of detectable viremia. Hepatology 2003; 38(4 Suppl. 1): 182A_Abstract.
- Helmer ME (2001):** Specific tetraspanin functions. J. Cell. Biol.; 155: 1103-1107.

- Henry IB, Nelson DA, Tomar RT and et al., (1984):** Clinical Diagnosis and Management By Laboratory Methods. 17th Ed. WB Saunders compay, Pheladelphia; P. 210.
- Herrerias JM, Company FP, Osorio M and et al., (1974):** Discrepancies entre el diagnostico laparoscòpico e histologico en la cirrosis hepàtica. Rev. Esp. Enf. Ap. (Eng. abstract) Digest.; 42:709-714.
- Hinoshita E, Taguchi K, Inokuchi A and et al., (2001):** Decreased expression of an ATP- binding cassette transporter, MRP2, in human livers with hepatitis C virus infection. J. Hepatol.; 35: 765-773.
- Hofer H, Watkins-Riedel T, Janata O and et al.(2003).** Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology; 37(1): 60–64.
- Honda M, Kaneko S, Saki A and et al. (1994):** Degree of diversity of HCV quasi-species and progression of liver disease. Hepatology 20:1144.
- Howell C, Jeffers L and Hoofnagle JH (2000):** Hepatitis C in African Americans: Summary of a workshop Gastroenterology; 181(5): 1528-36.
- Hsieh CS, Huang CC, Wu JJ and et al., (2001):** Ascending cholangitis provokes IL-8 and MCP-1 expression and promotes inflammatory cell infiltration in the cholestatic rat liver. J. Pediatr. Surg.; 36: 1623-1628.
- Huy TT and Abe K (2004):** Molecular epidemiology of hepatitis B and C virus infections in Asia. Pediatrics International. 2004;46:223–230.

Hynes RO (2002): Integrins: Bidirectional allosteric signaling machines. *Cell*; 110: 673-687.

Imbert-Bismut F, Ratziu V, Pieroni L and et al., (2001): Biochemical markers of liver fibrosis in patients with hepatitis C infection: a prospective study. *Lancet*; 357(7): 1069-1075.

Iredale JP, Murhy G, Hembry RM and et al (1992): Human hepatic lipocytes synthesize tissue inhibitor of metalloproteinase 1. Implications for regulation of matrix degradation in liver. *J Clin Invest* 1992; 90: 282-287.

Iredale JP, Benyon RC, Pickering J and et al. (1998): Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. *J Clin Invest* ; 102(3):538-549.

Iredale JP, Murhy G, Hembry RM and et al., (1992): Human hepatitis C lipocytes synthesize tissue inhibitor of metallo proteinase-1, Implications for regulation of matrix degradation in liver. *J. Clin. Invent.* 90: 282-7.

Irving W, Ball J, Berridges and et al., (1999): TTV infection in patients with hepatitis C: frequency persistence and sequence heterogenicity. *J. Infect. Dis*; 180(1): 27-34

Ishak K, Baptisa A, Bianchi L and et al., (1995): Histological grading and staging of chronic hepatitis. *J. Hepatol.*; 22:696-699.

Jaeckel E, Cornberg M, Wedemeyer H and et al. Treatment of acute hepatitis C with interferon alfa-2b. *N Engl J Med* 2001; 345: 1452–1457.

Januszkiewicz-Lewandowska D, Wvsocki J, Rembowska J and et al., (2003): Transmission of HCV infection among long-term

hospitalized once-hematological patients. J Hosp infect. 2003 feb; 53(2):120-3.

Johansen J, Christoffers P, Moller S and et al., (2000): Serum (YKL-40) a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur. J. Gastroenterol. Hepatol.; 12: 989.

Jones SL (1998): Role of haptoglobin in diagnosis of HELLP syndrome. Molecular Hematology; 11(3): 147-171.

Kanzler S, Beumann M, Schirmacher P and et al (2001): Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor β . J Viral Hepat; 8: 430-438.

Kaplan M, Gawrieh S, Cotler SJ and Jensen DM. (2003): Neutralizing antibodies in hepatitis C virus infection: a review of immunological and clinical characteristics. Gastroenterology 125: 597–604.

Kenny- Walsh E (1999): Clinical outcome after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N. Egnl. J. Med.; 340(16): 1228-33.

Khan JA, Khan FA, Dilawar M and et al., (2007): Serum hyalmonic acid as a marker of hepatic fibrosis. J Coll Physcians Smgpak; 17(6):323-6.

Kimberly LB (2005): Percutaneous liver biopsy coated from Handbook of Gastroenterologic procedure fifth Edition (11)P. 78-83, published by LIPPINCOTT WILLIAMS & WILKINS.

Kinnman N, Hultcrantz R, Barbu V and et al., (2000): Hepatic stellate cell proliferation is an early platelet- derived growth factor-mediated cellular event in rat cholestatic liver injury. Lab. Invest.; 81:1709-1716.

- Kinnman N, Hultcrantz R, Barbu V and et al., (2000):** PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. *Lab. Invest.*; 80:697-707.
- Kiyosawa K, Sodeyama T and Tanaka E (1994):** Hepatitis C virus infection in health care workers. In: Nishoka K, Suzuki H, Mishiro S, Oda T(eds.). *Viral hepatitis and liver disease*. Tokyo: Springer-Verlag, 479-482.
- Klatskin G and Conn HO (1993):** *Histopathology of the liver*. New York: Oxford University Press.
- Klatskin G and Conn HO (1993):** *Histopathology of the liver*. New York: Oxford University Press.
- Knauer MC (1978):** Percutaneous biopsy of the liver as a procedure for out patients. *Gastroenterology*; 74: 101-102.
- Knodell RG, Ishak KG, Black WC and et al., (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *J. Hepatology*; 1:431-435.
- Knodell RG, Ishak KG, Black WC and et al., (1981):** Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology*; 1: 431-435.
- Komurian-Pradel F, Paranhos-Baccalà G, Sodoyer M and et al., (2001):** Quantitation of HCV RNA using real-time PCR and fluorimetry. *J. Virol metnods*; 95(1-2): 111-9.
- Körner T, Kropf J and Gressner AM.(1996):** Serum laminin and hyaluronan in liver cirrhosis: markers of progression with high prognostic value. *J Hepatol* 1996; 25: 684-688.

- Lackner C, Struber G, Liegl B and et al., (2005):** Comparison and validation of simple non invasive tests for predication of fibrosis in chronic hepatitis C. *Hepatology*, 41(6): page 1376-81.
- Lazar H (1978):** Fractioned liver biopsy needles. *Gastroenterology*; 74:801.
- Le Frock JL, Ellis CA, Turchick JB and et al., (1975):** Transient bacteraemia associated with percutaneous liver biopsy. *J Infect Dis*; 131: S 104-107.
- Lebrec D (1996):** Various approaches to obtaining liver tissue: choosing the biopsy technique. *J. Hepatol.*; 25 (suppl. 1):20.
- Lebrec D, Goldfarb G, Degott C and et al., (1982):** Trans venous liver biopsy: an experience based on 1000 hepatic tissue sampling with this procedure *Gastroenterology*, 83:338-340.
- Leevy CM, Popper H and Sherlock S (1976):** Diseases of the liver and biliary tract. Standardization of nomenclature, diagnostic criteria and diagnostic methodology. DHEW publication on (NIH); 76-725.
- Leroy V, Monier F, Bottari S and et al., (2004):** Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. *Am J Gastroenterol*, 99(2):271-9.
- Lichtinghagen R, Huegel O, Seifert T and et al., (2000):** Expression of matrix metalloproteinase-2 and metalloproteinase-9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. *Clin. Chemistry*; 46:183-192.

- Louagie HK, Brouwer JT, Delanghe JR and et al., (1996):** Haptoglobin polymorphism and chronic hepatitis C. *J. Hepatol.*; 25: 10-14.
- Ludwig J (1993):** The nomenclature of chronic active hepatitis: an obituary. *Gastroenterol.*; 105: 274-278.
- Manns MP, McHutchison JG, Gordon SC and et al., (2001):** Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet*, 358: 958-65.
- Marco M (2000):** Diagnosis of hepatitis C virus infection file://A:\The Dody treatment Action group the Hepatitis Report: July, 9-14 html.
- Marra F (1999):** Hepatic stellate cells and the regulation of liver inflammation. *J. Hepatol.*; 21:1120-1130.
- Marra F, Arrighi MC, Fazi M and et al., (1999):** ERK- activation differentially regulates PDGFs actions in hepatic stellate cells and is induced by in vivo liver injury. *Hepatology*; 30:951-958.
- Marra F, De Franco R, Grappone C and et al., (1998):** Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. *Am. J. Pathol.*; 152: 423-430.
- Marrocca A, Carloni V, Sciammetta S and et al., (2002):** Expression of transmembrane 4 superfamily (TM4SF) proteins and their role in hepatic stellate cell motility and wound healing migration. *J. Hepatol.*; 37:322-330.
- Mastromattes AM, Rapaccini GL, Pompili M and et al., (2001):** HCV infection: other biological fluids than blood may responsible for Intra-familial spread. *Hepato-gastroenterology*, 2001 Jan-Feb; 48(37):193-6.

Maugat S, Astagneau P, Thibault V and et al., (2003): Nosocomial risk factors of hepatitis C infection. A multicenter study in hospital based populations. *Rev Epidemiol Sante Publique*, 2003 Jun; 51(3), 301-8.

McHutchinson JG, Blau LM, DeMedina M and et al.(2000): Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. *J Gastroenterol Hepatol*; 15: 945-951.

Mechan RP(1991): Receptors for Laminin on mammalian cells, federation of American societies of experimental Biology, 5:2538-46.

Mehta SH, Cox A, Hoover DR and et al.(2002) Protection against persistence of hepatitis C. *Lancet* ; 359: 1478–1483.

METAVIR: The French METAVIR Cooperative Study Group (1994): Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. *Hepatology*, 20: 15-20.

Michael LB, Edward PF and Larry S (2005): Amino acids and proteins; 8: 196-197. In: *Clinical Chemistry; principles, procedures and correlations*. 5th ed. Lippincott Williams & Wilkins, Philadelphia USA.

Michael P and Nezam H (2003): Serum markers of hepatic fibrosis. [www. Uptodate.com](http://www.Uptodate.com).

Mizukoshi E, Eisenbach C, Edlin B and et al., (2003): HCV-specific cellular immune responses in subjects who are anti-HCV negative, HCV RNA negative despite long-term (>15 years) injection drug use. *Hepatology*; 38(4 Suppl. 1): 210A_Abstract111.

Murawaki Y, Ikuta Y, Idobe Y and Kawasaki H (1999): Serum matrix metalloproteinase-1 in patients with chronic viral hepatitis. J. Gastroenterol Hepatol, 14: 138-45.

Murawaki Y, Ikuta Y, Idobe Y and et al., (1997): Tissue inhibitor of metalloproteinase-1 in the liver of patients with chronic liver disease. J Hepatol ; 26(6):1213-1219.

Murawaki Y, Ikuta Y, Koda M and Kawasaki H (1994): Serum type III procollagen peptide, type IV collagen 7S domain, central triplehelix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology, 20:780-7.

Murawaki Y, Ikuta Y, Nishimura Y and et al.(1995): Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol ; 23: 145-152.

Murawaki Y, Koda M, Okamoto K and et al., (2001): Diagnostic value of serum type IV collagen test in comparison with platelet count for predicting the fibrotic stage I patients with chronic hepatitis C. J. Gastroenterol. Hepatol.; 16: 777.

Murawaki Y, Yamada S, Ikuta Y and Kawasaki H (1999): Clinical usefulness of serum matrix metalloproteineinase-2 concentration in patients with chronic viral liver disease. J Hepatol, 30: 1090-8.

Myers RP, Messous D, Thabut D and et al., (2002): The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C. Prospective validation in 534 patients. Hepatology; 36: 351A (Abstract).

- Myers RP, Ratziu V, Imbert-Bismut F and et al., (2002):** Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. *Am J Gastroenterol*, 97:2419-25.
- Nakamura T, Tomita Y, Hirai R and et al.,(1985)** Inhibitory effect of transforming growth factor- β on DNA synthesis of adult rat hepatocytes in primary culture. *Biochem Biophys Res Commun*; 133:1042-1050.
- National Institute of Health(2002)** Consensus Statement on Management of Hepatitis C:. NIH Consensus State Sci Statements 2002, 19: 1-46.
- Naveau S, Poynard T, Benattar C and et al., (1994):** Alpha-2-macroglobulin and hepatic fibrosis. Diagnostic Interest. *Dig. Dis. Sci.*; 39: 2426-2432.
- Nellson DR, Gonzales-Peralta RP, Qian K and et al., (1997):** Transforming growth factor- β 1 in chronic hepatitis. *J Viral Hepat*; 4: 29-35.
- Ngo Y, Munteanu M, Messous D and et al., (2006):** A prospective analysis of the prognostic value of biomarkers (fibrotest) in patients with chronic hepatitis C. *Clin Chem*; 52(10): 1887-96.
- Ngugen MH, Whittemore AS, Gracia RT and et al., (2009):** Role of ethnicity in risk for hepatocellular cancer in patients with chronic hepatitis C are cirrhosis. *Clin Gastroenterol, Hepatol*. 2(9):820-4.
- Nicholls DG and Budd LS (2000):** Mitochondria and neuronal survival. *Physiol. Rev.*; 80: 315- 360.

- Nicolau C, Bianchi L and Vilana R (2002):** Gray-scale ultrasound in hepatic cirrhosis and chronic hepatitis: diagnosis, screening and intervention. *Seminars in US, CT and MRI*;23:3–18.
- Nishiura T, Watanabe H, Matsuoka Y and et al., (2005)** "Ultrasound evaluation of the fibrosis stage in chronic liver disease by simultaneous use of low and high frequency probes" *British Journal of radiology* 78, 189 – 197
- Oberti F, Valsesia E, Pilette C and et al., (1997):** Noninvasive diagnosis of hepatic fibrosis or cirrhosis. *Gastroenterology.*; 113:1609–1616
- Pagliaro L, Rinaldi F, Craxi A and et al., (1983):** Percutaneous blind biopsy versus laparoscopy with guided biopsy in diagnosis of cirrhosis. A prospective, randomized trial. *Dig. Dis. Sci.*; 28:39-43.
- Paradis V, Mathurin P, Ratziu V and et al., (1996):** Binding of apolipoprotein A1 and acetaldehyde-modified apolipoprotein A1 to liver extracellular matrix. *Hepatology*; 23: 1232-1238.
- Parola M and Robino G (2001):** Oxidative stress-related molecules and liver fibrosis. *J. Hepatol.*; 35: 297- 306.
- Patch D, (2005):** Liver biopsy chapter 134 coated from clinical gastroenterology and hepatology 1st Edition. Page 987 to 991 chapter 134.
- Patel K, Gordon SC, Jacobson I and et al.(2004):** Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. *J Hepatol*;41:935–42.
- Patel K, Lajoie A, Heaton S and et al., (2003):** Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. *J Gastroenterol Hepatol*, 18(3): 253-7.

- Pawlotsky JM (2006):** Virology of hepatitis B and C viruses and antiviral. *Journal of Hepatology* 44 (2006), 10-13.
- Pawlotsky JM, LonJon I, Hezode C and et al., (1998):** What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories. *Hepatology*; 27(6): 1700-2.
- Pawlotsky JM, Prescote L, Simmonds P and et al., (1997):** Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. *J Clin Microbiol.*; 35(7): 1734-9.
- Pawlotssky JM (2002):** Use and interpretation of virologic tests for hepatitis C. *Hepatology*, 36(1): 965-73.
- Peck–Radoslavljivic M. (2001)** Hypersplenism. *Eur J Gastroenterol Hepatol* ; 13: 317-323.
- Penin F, Dubuisson J, Rey FA and et al., (2004):** Structural biology of HCV. *Hepatology* 2004; 39: 5-19.
- Persijn JP and Van der Slik W (1986):** A new method for determination of gamma glutamyl transferase in serum. *J. Clin. Chem, Clin. Biochem.*; 18: 421-427.
- Pessoa MG and Wright TL (1997):** HCV infection in transplantation. *Clin liver Dis*, 1997 Nov; 1(3); 663-90.
- Piccinino F, Sagnelli E, Easquale G and et al., (1986):** Complications following percutaneous liver biopsy: a multicentre retrospective study on 68, 276 biopsies. *J. Hepatology*; 2:165.
- Piccinnio F, Sagnelli E, Pasquale G and Giusti G (1986):** Complications following percutaneous liver biopsy. A multicentre retrospective study on 68, 276 biopsies *J Hepatol.* 2: 165-173.

- Pietrangela A (1996):** Metals, Oxidative stress and hepatic fibrogenesis. Semin. Liver Dis.; 16: 13-30.
- Pilette C, Oberti F, Aube C and et al.(1999)** Non invasive diagnosis of esophageal varices in chronic liver disease. J Hepatol; 31: 867-873.
- Pinzani (2006):** Non- invasive evaluation of hepatic fibrosis: don't count your chicken before they're hatched Gut, 55: 310 – 312.
- Pinzani M (2000):** Liver fibrosis. Springer Semin. Immunopathol.; 21:475-490.
- Pinzani M (2004):** Pathogenesis of hepatic fibrosis (p. 121-129). In liver Disease from bench to bedside. American Association for the study of liver disease. Massachusetts, October 29-30.
- Pinzani M and Marra F (2001):** Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis ,21: 397-416.
- Pinzani M, Romanelli RG and Magli S (2001):** Progression of fibrosis in chronic liver diseases: time to tally the score. J. Hepatol.; 34: 764-767.
- Pinzani M, Rombouts K and Colagrande S (2005):** Fibrosis Chronic liver diseases: diagnosis and management. J Hepatol. 42: S12-S36.
- Plebani M and Burlina A (1991):** Biochemical markers of hepatic fibrosis. Clin. Biochem. 24(3): 219-39.
- Polyak SJ and Gretch DR (1996):** Molecular diagnostic testing for viral hepatitis: Methods of application. In: Wilson RA, ed. Viral hepatitis diagnosis, treatment and prevention. New York: Marcel Dekker, 1-33.

- Ponchon T (1997):** Transmission of hepatitis C and prion disease through digestive endoscopy: Evaluation of risk and recommended practices *Endoscopy*, 29: 199-202.
- Poniachik J, Bernstein DE, Reddy KR and et al., (1996):** The role of laparoscopy in the diagnosis of cirrhosis. *Gastrointest. Endosc.*; 43: 568-571.
- Popper H and Piez KA (1978):** Collagen metabolism in the liver. *Dig. Dis.*; 23: 641.
- Poynard T, Imbert-Bismut F, Munteanu M and Ratziu V. (2005):** FibroTest-FibroSURE: towards a universal biomarker of liver fibrosis? *Expert Rev Mol Diagn* , 5: 15-21.
- Poynard T, Bedossa P , METAVIR and CLINIVIR cooperative study groups (1997):** Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. *J. Viral Hepatitis*; 4(3): 199-208.
- Poynard T, Bedossa P and Opolon P (1997):** Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR and DOSVIRC groups. *Lancet*; 349: 825-832.
- Poynard T, Bedossa P, Mathurin P and et al., (1995):** Apolipoprotein A1 and hepatic fibrosis. *J. Hepatol.*; 22: 107-110.
- Poynard T, Imbert-Bismut F, Ratziu V and et al., (2002):** Biochemical markers of liver fibrosis in patients infected by Hepatitis C virus: Longitudinal validation in a randomized trial. *J Viral Hepat.*, 9:128-133.
- Poynard T, Munteanu M, Imbert-Bismut F and et al., (2004):** Prospective analysis of discordant results between biochemical

markers and biopsy in patients with chronic hepatitis C. Clin chem.. 50 (8): 1344-55.

Poynard T, Ratziu V and Bedossa P (2000): Appropriateness of liver biopsy C. J. Gastroenterol.; 14: 543-548.

Poynard T, Ratziu V, Benmanov Y and et al., (2000): Fibrosis in patients with chronic hepatitis C: Detection and significance, Seminars in liver disease Vol. 20. No.1.

Poynard T, Yuen MF, Ratziu V and Lai CL (2003): Viral hepatitis C. Lancet; 362(9401): 2095-100.

Prati D (2006): Transmission of hepatitis C virus by blood transfusions and other medical procedures: A global review. Hepatology J. 45: 607-16.

Preikasitis JK, Fenton J, Banton I and et al., (1997): Serologic Responses to Hepatitis C in solid organ transplant Recipient Serological responses to HCV are often delayed or absent in these patients and assay for HCV RNA should considered as a primary screening test for the detection of HCV infection in the population.

Quer J and Esteban JI (1997): Epidemiology and prevention of hepatitis C virus infection. In: Hepatitis C 1997: Essays and Diagnosis and Therapy. Abbott Diagnostics Division, 26-38.

Regev A, Berho M, Jeffers LJ and et al., (2002): Sampling error and intraobserver variation in liver biopsy in patients with chronic HCVinfection. Am. J. Gastroenterol.; 97:2614-8.

Reichert CM, Wiesenthal LM and Klein HG (1983): Delayed hemorrhage after percutaneous liver biopsy. J. Clin. Gastroenterol; 5: 263- 266.

- Roitt I, Brostoff J and Male D (2002):** Introduction to the immune system (1): 1-13. In Immunology, 6th ed., Elsevier Science Limited.
- Rosalki SB (1975):** Gamma glutamyl transpeptidase. Adv. Clin. Chem.; 17: 53.
- Roskams T and Desmet V (1998):** Ductular reaction and its diagnostic significance. Semin. Diagn. Pathol.; 15:259-269.
- Rossi E, Adams L, Prins A and et al., (2003):** Validation of the Fibro Test biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem, 49(3):450-4.
- Sanderson N, Factor V, Nagy P and et al., (1995):** Hepatic expression of mature transforming growth factor beta-1 in transgenic mice results in multiple tissue lesions. Proc. Natl. Acad. Sci. USA; 92: 2572-2576.
- Sasaki H, Pollard RB, Schmitt D and Suzuki F (1992):** Transforming growth factor- β in the regulation of immune response. Clin Immunol Immunopathol; 65:1-9.
- Sasaki N, Matsui A, Monoi M and et al., (1997):** Loss of circulating hepatitis C virus in children who developed a persistent carrier state after mother to baby transmission. Pediatr. Res.; 42(3): 263-7.
- Scheurer PJ, Ashrafzadeh P, Sherlock S and et al., (1992):** The Pathology of hepatitis C. Hepatology; 15: 567.
- Schuppan D (1990):** Structure of the extracellular matrix in normal and fibrotic liver: collagens and glycoproteins. Semin. Liver. Dis. 10:1.
- Schuppan D, Krebs A, Bauer M and Hahn EG (2003):** Hepatitis C and liver fibrosis. Cell Beath Differ, 10 Suppl. 1:S59-67.

- Schuppan D, Krebs A, Bauer M and Hahn EG. (2003):** Hepatitis C and liver fibrosis. *Cell Death Differ*, 10(Suppl 1):S59-67.
- Schuppan D, Ruehl M, Somasundaram R and et al., (2001):** Matrix as a modulator of hepatic fibrogenesis. *Semin. Liver Dis.*; 21: 351-372.
- Sedlacek N, Jia JD, Bauer M and et al., (2001):** Proliferating bile duct epithelial cells are a major source of connective tissue growth factor in rat biliary fibrosis. *Am. J. Pathol.*, 158: 1239-1244.
- Seef LB, Hollinger FB, Alter HJ and et al., (1998):** Long-term mortality and morbidity of transfusion-associated of non-A non-B and type C hepatitis: A national Heart, Lung Hepatology, 33(2): 455-463.
- Seeff LB (2002):** Natmol history of chronic hepatitis C. *Hepatology*; 36 (5 suppl1): S35-S48.
- Seeff LB (2002):** Natural history of chronic hepatitis C. *Hepatology*; 36: S35-S46.
- Serfaty L, Aumôiter H, Chazouillères O and et al., (1998):** Determinants of outcome of compensated hepatitis C virus relates cirrhosis. *Hepatology*. 27 (5): 1435-40.
- Sherlock S and Dooley J (2002):** Anatomy and function; Biopsy of the liver and hepatic cirrhosis. In *Diseases of the liver and Biliary system "11th Edition"*, Blackwell Sc. Publ., Oxford, London, Edinburgh, (1): 1-16; (3): 37-44 and (21): 365-377.
- Sherlock S and Dooley J (2002):** Anatomy and function (1): 1-16; Biopsy of the liver (3): 37-44 and Hepatic cirrhosis (21): 365-377. In *Diseases of the liver and Biliary system "11th Edition"*, Blackweel Sc. Publ., Oxford London, Edinburgh.

- Sherlock S, Dick R and Van Leeuwen DJ (1984):** Liver biopsy today. The Royal Free Hospital experience. *J. Hepatol.*; 1:75.
- Sherlock S and Dooley J (1997):** Diseases of the liver and biliary system, 10th ed. London: Black well scientific; Chapter (3): page 33-42.
- Simmonds F, Bukh J, Combet C and et al., (2005):** Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. *Hepatology* 2005; 42:962-973.
- Simmonds P (1999):** Viral heterogeneity of hepatitis C virus. *J. Hepatol.* 1999; 31 (Suppl-1): 54.
- Simpson KJ, Lukacs NW, Colletti L and et al., (1997):** Cytokines and the liver. *J. Hepatol.*; 27: 1120.
- Spirli C, Nathanson MH, Fiorotto R and et al., (2001):** Pro-inflammatory cytokines inhibit secretion in rat bile duct epithelium. *Gastroenterol.*; 121: 156-169.
- Stavbier RE and Lackner C (2007):** Non-invasive diagnosis of hepatic fibrosis in chronic hepatitis C. *World J. of Gastroenterology*; 13(32): 4287-4294.
- Stefanovic B, Hellerbrand C, Holick M and et al., (1997):** Post-transcriptional regulation of collagen alpha (I)-mRNA in hepatic stellate cells. *Mol. Cell. Biol.*; 17: 512.
- Stephen LC and Timothy RM (2006):** The normal history of HCV infection. *Int. J. Med. Sci*; 3(2): 47-52.
- Takeda T, Takahiro Y, Nakeryama Y and et al., (2006):** Usefulness of non invasive transient elastography for assessment of liver fibrosis stage in chronic hepatitis C. *World J Gastroenterol*; 28; 12(48): 7768-73.

- Tang S and Lai KN (2005):** Chronic viral hepatitis in hemodialysis patients. *Hemodial. Int*; 9:169-79.
- Teare JP, Sherman D, Greenfield SM and et al., (1993):** Comparison of serum procollagen III peptide concentrations and PGA Index for assessment of hepatic fibrosis *Lancet*. 342:895-898.
- Teare JP, Sherman D, Greenfield SM and et al., (1993):** Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. *Lancet*; 342(8876): 895-8.
- Theodossi A, Siegelhalter D, Portmann B and el al., (1983):** The value of clinical, biochemical, ultrasound and liver biopsy data in assessing patients with liver diseases. *Liver*; 3: 315-326.
- Tiggelman AM, Linthors C, Boers W and et al., (1997):** Transforming growth factor-beta-induced collagen synthesis by human liver myofibroblasts is inhibited by alpha-2 macroglobulin. *J. Hepatol.*; 26: 1220-1228.
- Torriani FJ, Rodriguez-Torres M, Rockstroh JK and et al.(2004)** Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. *N Engl J Med*, 351: 438-50.
- Tran A, Hastier P, Barjoan EM and et al., (2000):** Noninvasive predication of severe fibrosis in patients with alcoholic liver fibrosis *Gastroenterol. Clin.Biol.*; 24: 626-630.
- Tüney D, Aribal ME, Ertem D and et al., (1998):** Diagnosis of liver cirrhosis in children based on colour Doppler ultrasonography with histopathological correlation. *Pediatr Radiol*; 28:859–64.
- Vaheri A, Salonen EM, Vartio T and et al., (1985):** Fibronectin in formation and degradation of the pericellular matrix. In: *Fibrosis*. Ciba. Foundation Symposium. 114(ed.). Pitman. London; P. 111.

- Vicente Carreño (2006):** Occult hepatitis C virus infection: A new form of hepatitis C *World J Gastroenterol* November 21; 12(43): 6922-6925
- Villano SA, Valhov D, Nelson KE and et al., (1991):** Persistence of viremia and the importance of long term follow-up after acute hepatitis C infection *Hepatology*; 29: 908-14.
- Villeneuve JP, Bilodeau M, Lepage R and et al., (1996):** Variability in hepatic iron concentration measurement from needle biopsy specimens. *J. Hepatol.*; 25:172.
- Vogt M, Lang T, Frosner G and et al., (1999):** Prevalence and Clinical outcome of hepatitis C in children who under went cardiac surgery before the implementation of blood donor screening. *N Engl. J. Med*; 341(12):866-870.
- Vozar I (2005):** Serum laboratory markers for non-invasive diagnosis and monitoring of liver fibrogenesis in patients with chronic liver disease. *Bratislav Lek Listy*; 106(3): 123-126.
- Wai C, Greenson JK, Fontana RJ and et al., (2003):** A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*; 38: 518-526.
- Wai C, Greenson JK, Fontana RJ and et al., (2003):** A simple non invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. *Hepatology*, 38: 518-26.
- Wai CT, Greenson JK, Fontana RJ and et al., (2003):** A simple non in-
voire Index can predict both significant fibrosis and cirrhosis in
patients with Chronic hepatitis C. *Hepatology* 38:518-526.

- Walsh KM, Fletcher A, McSween RN and et al., (2000):** Basement membrane peptides as markers of liver disease in chronic hepatitis C. *J. Hepatol.*; 32: 325.
- Walsh KM, Timms P, Campbell S and et al., (1999):** Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinase-1 and-2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C. Comparison using ROC analysis. *Dig Dis Sci*; 44: 624-630.
- Wasley A and Alter MJ (2000):** Epidemiology of hepatitis C: geographic differences and temporal trends. *Semin Liver Dis.*; 20: 1-16.
- Watanbe N, Nishizaki Y, Kojima S and et al., (2006):** Clinical significance of serum matrix Metalloproteinase and tissue inhibitors of Metalloproteinases in Chronic liver disease. *Tokai J Exp Clin Med.*, 31(3):96-101.
- Westin J, Lagging LM, Wejstal R and et al., (1999):** Inter-observer study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. *liver*; 19:183-187.
- Whitmire LF, Galambos JT, Philips VM and et al., (1985):** Imaging guided percutaneous hepatic biopsy: diagnostic accuracy and safety. *J. Clin. Gastroenterol.*; 7:511.
- Wiese M, Berr F, Lafrenz M and Porst H (2000):** Low frequency of cirrhosis in hepatitis C (genotype 1b) single-source outbreak in Germany: a 20-year multicenter study. *Hepatology*; 32(1): 91-6.
- Wiese M, Berr F, Lafrenz M and et al., (2000):** Low frequency of cirrhosis in a hepatitis C (genotype 1b) single- source outbreak in Germany: a 20-year multicenter study. *Hepatology*; 32: 91-6.

Wiley TE, McCarthy M, Breidi L and Layden TJ (1998): Impact of alcohol on the histological and clinical progression of hepatitis C infection. *Hepatology*; 28: 805-809.

Wong JB and Koff RS (2000): Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. *Ann. Intern. Med.*; 133: 665-675.

www.oxisresearch.com.

www.statsoft.com.

Yano M, Kumada H, Kage M and et al., (1996): The long term pathological evaluation of chronic hepatitis C. *Hepatology*; 23:1334-40.

Yeh WC, Li PC, Jeng YM and et al., (2002) Elastic modulus measurements of human liver and correlation with pathology. *Ultrasound Med Biol*; 28: 467-474

Zakaria N, Knisely A, Portmann B and et al., (2003): Acute sickle cell hepatopathy represents a potential contraindication for percutaneous liver biopsy. *Blood*; 101: 101-103.

Zakim D and Boyer TD (1996): Fibrosis: representative molecular elements, a basic concept and emerging targets for suppressive treatment (15): 465-498, Hepatic fibrosis and cirrhosis (16): 506-520 and Evaluation of liver function (28): 782-825. In: *Hepatology. A text-book of Liver Disease*, 3rd ed., Library of Congress, USA.

Zeuzem S, Buti M, Ferenci P and et al., (2006): Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. *J Hepatol* , 44:97-103.

Zhang BB, Min Cai W, Weng HL and et al., (2003): Diagnostic value of platelet derived growth factor–BB, transforming growth factor- α 1, matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol; 2490-2496.

Zignego AL, Ferri C, Pileri SA and et al., (2007): Extrahepatic manifestations of hepatitis C virus infection: A general overview and guidelines for a clinical approach. Digestive and liver disease volume 39 :(1) 2-17.